Valeria Santini, MD

home / authors / valeria-santini-md

Articles

A panel of 3 experts on myelodysplastic syndrome

Unmet Needs and Future of Lower-Risk MDS

Uwe Platzbecker, MD;Rami Komrokji, MD;Valeria Santini, MD

October 19th 2023

The panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.

Rami Komrokji, MD, an expert on myelodysplastic syndrome

Treatment Strategies and Sequencing in MDS

Uwe Platzbecker, MD;Rami Komrokji, MD;Valeria Santini, MD

October 12th 2023

Rami Komrokji, MD, provides clinical insights on treatment decision-making, sequencing, and combinations for patients with myelodysplastic syndrome. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Valeria Santini, MD, an expert on myelodysplastic syndrome

Real-World Data for Luspatercept in Lower-Risk MDS

Uwe Platzbecker, MD;Rami Komrokji, MD;Valeria Santini, MD

October 12th 2023

Valeria Santini, MD, reviews data from real-world outcomes in clinical trials investigating luspatercept in patients with lower-risk MDS.

Clinical Implications of Recent Data on New Agents in Lower-Risk MDS

Uwe Platzbecker, MD;Rami Komrokji, MD;Valeria Santini, MD

October 5th 2023

Expert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome.

Recent Updates for Second-Line Treatment Options in Lower-Risk MDS

Uwe Platzbecker, MD;Rami Komrokji, MD;Valeria Santini, MD

October 5th 2023

The panel of experts review recent data updates for new agents being investigated in the second line in patients with lower-risk MDS.

Uwe Platzbecker, MD, an expert on myelodysplastic syndrome

MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS

Uwe Platzbecker, MD;Rami Komrokji, MD;Valeria Santini, MD

September 28th 2023

Uwe Platzbecker, MD, reviews data updates from the MEDALIST trial investigating luspatercept in patients with lower-risk myelodysplastic syndrome.

Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?

Uwe Platzbecker, MD;Rami Komrokji, MD;Valeria Santini, MD

September 28th 2023

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Clinical Insights into the COMMANDS Trial

Uwe Platzbecker, MD;Rami Komrokji, MD;Valeria Santini, MD

September 21st 2023

The expert panel reviews updated data from the COMMANDS trial on luspatercept in patients with lower-risk MDS and discusses their effect on clinical practice. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Myelodysplastic Syndrome: Overview of Diagnosis, Classification, and Treatment

Uwe Platzbecker, MD;Rami Komrokji, MD;Valeria Santini, MD

September 21st 2023

A panel of expert hematologists give an overview of myelodysplastic syndrome, focusing on diagnosis, classification, and treatment practices.